Ultragenyx Pharmaceutical (RARE) Competitors $45.40 -0.38 (-0.83%) (As of 12/16/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RARE vs. MRNA, VTRS, GMAB, SMMT, SRPT, RDY, PCVX, CTLT, QGEN, and ROIVShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Catalent (CTLT), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Moderna Viatris Genmab A/S Summit Therapeutics Sarepta Therapeutics Dr. Reddy's Laboratories Vaxcyte Catalent Qiagen Roivant Sciences Moderna (NASDAQ:MRNA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings. Which has more risk and volatility, MRNA or RARE? Moderna has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Do institutionals & insiders hold more shares of MRNA or RARE? 75.3% of Moderna shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 15.7% of Moderna shares are held by insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to MRNA or RARE? In the previous week, Moderna had 16 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 25 mentions for Moderna and 9 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.05 beat Moderna's score of 0.37 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 8 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MRNA or RARE more profitable? Moderna has a net margin of -43.77% compared to Ultragenyx Pharmaceutical's net margin of -106.93%. Moderna's return on equity of -17.68% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-43.77% -17.68% -13.35% Ultragenyx Pharmaceutical -106.93%-187.12%-37.55% Which has better valuation & earnings, MRNA or RARE? Ultragenyx Pharmaceutical has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$5.06B3.18-$4.71B-$5.82-7.19Ultragenyx Pharmaceutical$522.75M8.02-$606.64M-$6.47-7.02 Does the MarketBeat Community favor MRNA or RARE? Ultragenyx Pharmaceutical received 617 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 77.40% of users gave Ultragenyx Pharmaceutical an outperform vote while only 55.35% of users gave Moderna an outperform vote. CompanyUnderperformOutperformModernaOutperform Votes21255.35% Underperform Votes17144.65% Ultragenyx PharmaceuticalOutperform Votes82977.40% Underperform Votes24222.60% Do analysts recommend MRNA or RARE? Moderna currently has a consensus price target of $79.50, suggesting a potential upside of 90.01%. Ultragenyx Pharmaceutical has a consensus price target of $87.46, suggesting a potential upside of 92.65%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 11 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.14Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 SummaryUltragenyx Pharmaceutical beats Moderna on 10 of the 19 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.19B$6.40B$4.98B$9.32BDividend YieldN/A3.06%4.85%4.01%P/E Ratio-7.0210.62103.2117.62Price / Sales8.02300.631,299.0482.42Price / CashN/A56.6541.3438.32Price / Book13.555.434.864.93Net Income-$606.64M$150.96M$117.35M$225.47M7 Day Performance-7.95%-5.35%14.41%-1.15%1 Month Performance1.45%0.66%18.99%5.92%1 Year Performance-1.24%18.54%38.20%22.97% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.591 of 5 stars$45.40-0.8%$87.46+92.6%-1.2%$4.19B$522.75M-7.021,276Positive NewsMRNAModerna4.4147 of 5 stars$44.44+3.5%$83.33+87.5%-51.4%$17.10B$6.85B0.005,600VTRSViatris1.8058 of 5 stars$12.72-1.3%$13.67+7.4%+22.0%$15.18B$15.43B-17.1938,000GMABGenmab A/S4.2742 of 5 stars$22.20+1.8%$45.20+103.6%-35.1%$14.69B$2.39B21.172,204Short Interest ↓SMMTSummit Therapeutics3.4001 of 5 stars$18.43-0.6%$34.00+84.5%+629.7%$13.59B$700,000.000.00105SRPTSarepta Therapeutics4.9126 of 5 stars$128.86+0.5%$175.55+36.2%+36.3%$12.31B$1.24B102.541,314Insider TradePositive NewsRDYDr. Reddy's Laboratories1.8687 of 5 stars$14.56-0.1%$17.00+16.8%+10.3%$12.15B$3.35B23.2827,048PCVXVaxcyte1.8093 of 5 stars$91.64-1.8%$147.50+61.0%+47.8%$11.42BN/A0.00160Positive NewsCTLTCatalent2.7655 of 5 stars$62.11+0.5%$63.40+2.1%+53.0%$11.27B$4.38B0.0016,900QGENQiagen4.2491 of 5 stars$43.97+1.3%$50.80+15.5%+3.7%$10.03B$1.97B112.265,967ROIVRoivant Sciences2.6844 of 5 stars$12.23-1.1%$17.93+46.6%+8.4%$8.90B$124.79M2.19860Positive News Related Companies and Tools Related Companies Moderna Alternatives Viatris Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Sarepta Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Vaxcyte Alternatives Catalent Alternatives Qiagen Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RARE) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
